PRMA Insights: The Roadmap to Pricing and Reimbursement Success

Scope of the NSCLC report

Comprehensive secondary research, experienced based insight and validation by payers and Key Opinion Leaders (KOLs) across markets underpins prmainsights™: The Roadmap to Pricing and Reimbursement Success in NSCLC:

Reporting of the regulatory nominations and key supporting data for the following targeted therapies:

Alimta

Avastin

Iressa

Tarceva

 

The current pricing and reimbursement landscape for NSCLC in the Top 7 major pharmaceutical markets:

US

UK

France

Germany

Spain

Italy

Japan

 

Reviews of NSCLC clinical guidelines as published by:

ASCO

NCCN

ESMO

Japanese Lung Cancer Society

National Medical Societies

 

The comprehensive review and assessment of all pricing and reimbursement and HTA decisions for targeted
therapies and all relevant chemotherapeutic backbones across all lines of therapy.

The assessments of over 25 HTA and pricing and reimbursement decisions recently made in NSCLC by the following bodies:

AIFA	CEPS	CMS	DGFPS	G-BA	InEK	IQWiG
MHLW	NICE	SMC	TC	UVEF

Find out more about the NSCLC report:

The report delivers         Scope of the report        Authors of the report